NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer: Continued Avastin Plus Chemotherapy After First Progression in Clinical Practice

NCT02287597

CompletedN/A

Sponsor: Hoffmann-La Roche

Conditions: Colorectal Cancer

Countries: Croatia

This local, non-interventional, cohort study of patients with metastatic colorectal cancer (mCRC) will prospectively collect data from standard clinical practice of second-line treatment with chemotherapy plus Avastin (bevacizumab). There will be no additional diagnostic or therapeutic procedures required by this study, apart from those performed in everyday clinical practice for second-line treatment of mCRC in Croatia.

Eligibility overview

Sex: ALL

Age: 18 Years to —

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria

Inclusion Criteria:

* Written informed consent
* Age \>/=18 years
* Metastatic colorectal cancer (mCRC) previously treated with systemic treatment for advanced disease containing Avastin and chemotherapy; first-line Avastin received according to the Summary of Product Characteristics (SmPC)
* First line progression-free survival (PFS) \>6 months
* Eligible for second-line chemotherapy regimen
* Period between first progression and start of second line treatment with Avastin and chemotherapy \</=6 weeks

Exclusion Criteria:

* Contraindications, warnings and precautions for use specified in the Avastin SmPC

Locations (4)

Osijek, Croatia
Split, Croatia
Zagreb, Croatia
Zagreb, Croatia